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20Ⅱ
(idiopathic pulmonary fibrosis), FiO 2 (fraction of inspiratory oxygen), ssDNA (single 21Ⅱ strand DNA), HPFs (high power fields), PCR (polymerase chain reaction), TNF-α
22Ⅱ
(tumor necrosis factor-alpha), mRNA (messenger RNA), IL-1β (interleukin-1 beta),
23Ⅱ
MPO (myeloperoxidase), NF-κB (nuclear factor-kappa B), cDNA (complementary 24Ⅱ DNA), RQ (relative quantity), GAPDH (glyceraldehyde 3-phosphate dehydrogenase),
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UPLC-MS (ultra performance liquid chromatography-mass spectrometry)
26Ⅱ
27Ⅱ
Central picture
28Ⅱ
Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model.
29Ⅱ
30Ⅱ
Central message
31Ⅱ
Pirfenidone attenuated deterioration of pulmonary function by suppressing 32Ⅱ inflammation in lung ischemia-reperfusion injury. 
Abstract
39Ⅱ
Objective: Lung ischemia-reperfusion injury (IRI) is one of the complications after lung 40Ⅱ transplantation resulting in morbidity and mortality. Pirfenidone (PFD), an anti-fibrotic 41Ⅱ agent for the treatment of idiopathic pulmonary fibrosis, is reported to have 42Ⅱ cytoprotective properties in various disease models. The purpose of this study was to
43Ⅱ
investigate the effect of PFD on lung IRI.
44Ⅱ
Methods: Male Lewis rats (260-290g) were divided into 3 groups: sham group (n=5),
45Ⅱ
warm ischemia (WI) group (n=10), and WI plus PFD (WI+PFD) group (n=10). The reperfusion. In the WI+PFD group, PFD (300mg/kg) was administered orally by gavage 49Ⅱ 30 minutes prior to ischemia. After reperfusion, arterial blood gas analysis, lung 50Ⅱ mechanics, lung wet-to-dry weight (W/D) ratio, and histological findings were obtained.
51Ⅱ
The gene expression of pro-inflammatory cytokines in lung tissue was measured by 52Ⅱ quantitative reverse transcription polymerase chain reaction.
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7Ⅱ Ⅱ
Materials and Methods
82Ⅱ
Animals
83Ⅱ
All experimental protocols received approval from the Ethics Committee of the
84Ⅱ
Graduate School of Medicine at Kyoto University.
85Ⅱ
We used male Lewis rats, 11 weeks-old, weighing 260-290g (Japan SLC, Hamamatsu, 86Ⅱ Japan).
87Ⅱ
88Ⅱ
Chemicals
89Ⅱ
PFD for administration to the animal was provided by Shionogi & Co., Ltd. (Osaka,
90Ⅱ
Japan).
91Ⅱ
PFD for concentration measurement was purchased from Tokyo Chemical Industry Co.
92Ⅱ
Ltd. (Tokyo, Japan) and carbamazepine was purchased from Sigma-Aldrich Co. (St.
93Ⅱ
Louis, MO, USA). All other chemicals were of the highest purity available.
94Ⅱ
95Ⅱ
This study consisted of 2 experiments (Experiment 1 and Experiment 2). Experiment 1
96Ⅱ
was to investigate the function and inflammatory change in the lung after 
101Ⅱ
Rat left hilar clamp model
102Ⅱ
Rats were randomly assigned to 3 groups: sham group (n=5), warm ischemia (WI) 103Ⅱ group (n=10), and WI plus PFD (WI+PFD) group (n=10). PFD (300 mg/kg) dissolved 104Ⅱ with 1ml of 0.5% carboxymethyl cellulose was administered orally by gavage in the 105Ⅱ WI+PFD group, and 1 ml of 0.5% carboxymethyl cellulose was administered in both
106Ⅱ
the sham group and the WI group.
107Ⅱ
All rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (120 108Ⅱ mg/kg). Tracheotomy and mechanical ventilation were performed with a tidal volume of 109Ⅱ 10 ml/kg, a respiratory rate of 70 breaths/min, a positive end-expiratory pressure of 2 110Ⅱ cmH 2 O and a fraction of inspiratory oxygen (FiO 2 ) of 1.0. Heparin (50 IU) was injected 111Ⅱ through the jugular vein, then a left thoracotomy at the fifth intercostal space was 112Ⅱ performed.
113Ⅱ
The sham group underwent 210 min of perfusion without ischemia. In the WI groups,
114Ⅱ
the left pulmonary hilum was occluded with a vascular clamp to induce warm ischemia 115Ⅱ 30 minutes after PFD or vehicle administration. During clamping of the left hilum, the 116Ⅱ tidal volume was adjusted to 6 ml/kg. After 90 minutes of ischemia, the clamp was
removed to begin reperfusion for 120 minutes and the tidal volume recovered to 10 118Ⅱ ml/kg.
119Ⅱ
120Ⅱ
Lung mechanics measurements
121Ⅱ
After 120 minutes of reperfusion, a median sternotomy was performed. The right 122Ⅱ pulmonary hilum was occluded with a vascular clamp, and the left lung was ventilated
123Ⅱ
with a tidal volume of 5 ml/kg for five minutes. Then, an arterial blood sample was 124Ⅱ obtained through the ascending aorta. After that, the rat was connected to a flexiVent 125Ⅱ (SCIREQ, Montreal, Quebec, Canada) to measure the left pulmonary function. We The upper part was used to calculate the lung wet-to-dry weight (W/D) ratio. The wet 134Ⅱ weight was measured soon after harvesting, and the dry weight was measured after 24
135Ⅱ
hours at 100 °C. The ratio was calculated as wet weight divided by dry weight.
136Ⅱ
137Ⅱ
Pathological evaluation
138Ⅱ
The middle part of the left lung was fixed in 10% formalin and stained with and nuclear factor kappa B subunit 1 mRNA (NF-κB mRNA). The tissue was stabilized
159Ⅱ
using RNAlater® (QIAGEN, Hilden, Germany) and RNA was extracted using an
160Ⅱ
RNeasy Plus Mini Kit® (QIAGEN, Hilden, Germany), according to the manufacturer's
161Ⅱ
protocol. The total RNA concentration was determined by spectrophotometer and the
162Ⅱ
quality was evaluated with a 260/280 nm ratio (1.8-2.0). Then, the total RNA was 163Ⅱ reverse transcribed to complementary DNA (cDNA) using Ready-To-Go You-Prime
164Ⅱ
First-Strand Beads® (GE Healthcare, Pittsburgh, PA). Each cDNA was diluted to 10 165Ⅱ µg/µl, and 2 µl of cDNA was mixed with the Thunderbird® probe qPCR Mix (Toyobo,
166Ⅱ
Osaka, Japan) and TaqMan Gene Expression Assay probe set (Thermo Fisher Scientific,
using the comparative ∆∆CT method. Glyceraldehyde 3-phosphate dehydrogenase 170Ⅱ (GAPDH) was used as a reference gene and the samples of the sham group were used as 171Ⅱ controls. Analysis of each sample was run in triplicate. The probes used for PCR were 172Ⅱ as follows: GAPDH (NM_017008), TNF-α mRNA ( NM_012675), IL-1 mRNA
Experiment 2
176Ⅱ
Concentration of PFD in rat hilar clamp model
177Ⅱ
PFD administration (300 mg/kg), 90 minutes clamping of the left hilum, and 120
178Ⅱ
minutes of reperfusion were performed as described in experiment 1 (n=10).
179Ⅱ
To confirm the concentration of PFD in the model, the ultra-performance liquid 180Ⅱ chromatography mass spectrometry (UPLC-MS) method was used. In this experiment, a
181Ⅱ
blood sample was collected through the inferior vena cava, and the lungs were harvested
182Ⅱ
at 30 minutes after PFD administration and 120 minutes after reperfusion (n=5, in each
times volumes and homogenized with a Polytron PT 1300 D (KINEMATICA AG,
187Ⅱ
Luzern, Switzerland).
188Ⅱ
Fifty microliters of collected plasma and the lung homogenized samples followed by the 189Ⅱ addition of 100 µL of methanol with the internal standard (IS) working solution
190Ⅱ
(carbamazepine 500 ng/mL) were used for measurement. After vortex-mixing for 1 min,
191Ⅱ
the sample was centrifuged at 13,000 rpm for 8 mins. The supernatant was injected into
192Ⅱ
an ACQUITY UPLC system (Waters Corp., Milford, MA, USA) for analysis. The 193Ⅱ standards were prepared in the same way.
194Ⅱ
The calibration curves were constructed in the concentration range of 5-2,000 ng/mL 195Ⅱ and samples exceeding 2,000 ng/mL were measured again with the appropriate dilution.
196Ⅱ
Chromatographic separation was achieved on an ACQUITY UPLC system with an
197Ⅱ
Acquity BEH C18 column, 2.1 mm × 50 mm, 1.7 µm particle size column (Waters Dunnett's t-test was then performed to determine difference. We also performed 212Ⅱ sensitivity analysis using Kruskal-Wallis test to make sure the results of ANOVA. The 
Results
218Ⅱ
Pulmonary function of the left lung
219Ⅱ
The results of the lung function analyses are shown in Fig. 1 .
220Ⅱ
Dynamic pulmonary compliance was significantly higher in the WI+PFD group than 221Ⅱ that in the WI group (p<0.01, Fig. 1A ). Airway pressure was lower in the WI+PFD 222Ⅱ group (p<0.05, Fig. 1B-C) . The WI+PFD group had better oxygenation levels (p<0.05, 223Ⅱ Fig 1D) .
224Ⅱ
225Ⅱ
Histological findings
226Ⅱ
The left lungs harvested from the sham group showed almost normal histology. In 227Ⅱ contrast, those from the WI group showed severe perivascular edema, alveolar wall 228Ⅱ swelling and hemorrhage into the alveolar area. These findings were ameliorated in the 229Ⅱ WI+PFD group, and the W/D ratio was significantly lower in the WI+PFD group 230Ⅱ compared to the WI group (p<0.05, Fig. 2A-D) . We measured the perivascular cuff area 231Ⅱ in histologic sections of lungs isolated from five sham (15 vessels), 10 WI (30 vessels),
232Ⅱ
and 10 WI+PFD (30vessels) animals. We calculated the index of perivascular cuff 233Ⅱ area/vessel area to eliminate variations due to vessel size. The index was significant 234Ⅱ lower in the WI+PFD group compared to the WI group (p<0.01, Fig 2E) .
The number of red blood cells in alveolar space was expressed by the average number 236Ⅱ in 5 randomly chosen high-power fields (HPFs) per section at a magnification of 400 237Ⅱ using dynamic cell count (BZ-analyzer, Keyence, Japan). The number was significant Ⅱ
238Ⅱ
lower in the WI+PFD group compared to the WI group (p<0.05, Fig 2F) .
239Ⅱ
The number of neutrophil infiltrations into the perivascular area was markedly increased
240Ⅱ
in the WI group as compared to the sham group. Neutrophil infiltration was
241Ⅱ
significantly lower in the WI+PFD group compared to the WI group (p<0.05, Fig. 3 ).
242Ⅱ
Immunostaining for ssDNA showed the number of apoptotic cells was lower in the
243Ⅱ
WI+PFD group compared to the WI group (p<0.05, Fig. 4 ).
244Ⅱ
245Ⅱ
Gene expression of TNF-α, IL-1β, and NF-κB in the lung tissue
246Ⅱ
Gene expression of TNF-α mRNA was significantly reduced in the WI+PFD group respectively. Fig. 5B, 5C ).
250Ⅱ
In the WI group, the expression of NF-κB mRNA was increased by 1.7-fold compared
251Ⅱ
to the sham group. However, in the WI+PFD group, the expression was only increased 
Comment
264Ⅱ
In the present study, we demonstrated that administration of PFD in lung IRI improved 265Ⅱ pulmonary function, oxygenation level, pulmonary edema, and neutrophil infiltration.
266Ⅱ
Furthermore, PFD decreased the number of apoptotic cells and pro-inflammatory 267Ⅱ cytokines in lung tissue.
268Ⅱ
There have been some reports that PFD suppresses fibrosis due to rejection and 269Ⅱ inflammatory change in the chronic or subacute phase after lung transplantation, 16-18 but
270Ⅱ
there are no reports of the acute phase, especially within 72 hours, after transplantation.
271Ⅱ
In this study, it was shown that administration of PFD was effective prior to the onset of 272Ⅱ lung IRI, which is the main cause of acute lung injury after lung transplantation. Liu H
273Ⅱ
reported that PFD inhibit lung fibrosis through decreasing TGF-β and arginase activity 274Ⅱ at 21 days after lung transplantation, but they did not evaluate acute lung injury. 18 In our 275Ⅱ study, we focused on lung IRI with administration of PFD. The results clearly showed 276Ⅱ that the lung IRI was alleviated from the acute phase by PFD through inhibition of 277Ⅱ TNF-α and NF-κB.
278Ⅱ
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19Ⅱ Ⅱ
The molecular target of PFD has yet to be identified. Previous reports have suggested 282Ⅱ direct inhibition of TNF-α and reduction of inflammatory cytokines via the NF-κB 283Ⅱ pathway. NF-κB is known as a crucial transcription factor of the inflammatory response.
284Ⅱ
Oxidation by reactive oxygen species causes the release of the inhibitory subunits of the 285Ⅱ NF-κB inhibitor and activation of NF-κB, which generate pro-inflammatory signaling.
21
286Ⅱ
In this study, PFD decreased NF-κB mRNA in the lung tissue as previously reported and
287Ⅱ
it had a protective effect on acute lung injury. Moreover, NF-κB and TNF-α have an 288Ⅱ effect on cell survival. 22, 23 The present study showed that PFD significantly decreased
289Ⅱ
both of these and reduced apoptotic cells in the immunohistochemical staining of
290Ⅱ
ssDNA on lung IRI. The staining with anti-ssDNA antibody was a specific and sensitive
291Ⅱ
procedure for the detection of apoptotic cells compared to TUNEL staining.
24
292Ⅱ
In experiment 2, our results demonstrated that administration of PFD orally by gavage
293Ⅱ
in a rat IRI model increased concentration of PFD in blood and lung tissue within the 294Ⅱ experimental period.
25-27
295Ⅱ
Several limitations of this study should be acknowledged. Pirfenidone had a protective 296Ⅱ effect on lung IRI in a rat hilar clamp model, but our findings cannot be directly applied clamp/vascular occlusion model has been utilized in the study of IRI in other organs 300Ⅱ such as kidney, liver and intestine. 13, 14, [28] [29] [30] Second, the hilar clamp model is a simpler
301Ⅱ
and more consistently reproducible procedure when compared to a transplant model.
302Ⅱ
For a proof-of-concept experiment examining PFD, the clamp model was employed to 303Ⅱ limit variability in IRI.
304Ⅱ
However, the hilar-clamp model differs from clinical lung transplantation in three
305Ⅱ
aspects. The first is the difference in ischemic condition. In this experiment, reperfusion
306Ⅱ
occurs after warm ischemia alone. In contrast, lung transplantation involves a period of reperfused donor lung will be exposed to zero to low doses of recipient-derived PFD. In 312Ⅱ this study, it cannot be distinguished whether PFD in the donor lung is effective during 313Ⅱ ischemia or PFD in the blood and/or donor lung is effective for the reperfusion.
314Ⅱ
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21Ⅱ Ⅱ that in lung transplantation it will only be administered to the recipient, it is necessary to 318Ⅱ consider using the transplant model with administration of PFD only in the recipient.
319Ⅱ
Third, the response of the immune system of rats is different from that of humans. We 320Ⅱ need to confirm our findings in other animal models before applying these results to 321Ⅱ humans.
322Ⅱ
This was an observational study of the effects of PFD and we did not clarify the drug's 323Ⅱ mechanism. Further investigation will be necessary to define the mechanism associated 324Ⅱ with the protective effect of pirfenidone.
325Ⅱ
In conclusion, PFD administration before ischemia attenuated lung IRI through 326Ⅱ inhibition of pulmonary edema, production of pro-inflammatory cytokines, and 327Ⅱ apoptosis in a rat model. PFD may be useful as a new option for treatment of lung IRI. 
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Arrows indicate perivascular edema.
438Ⅱ
Bars and error bars show mean and standard error of mean; *p<0.05, **p<0.01 
457Ⅱ
Gene expression of TNF-α and NF-κB mRNA were significantly reduced in the
458Ⅱ
WI+PFD group compared to the WI group.
459Ⅱ
Bars and error bars show mean and standard error of mean; *p<0.05 
